Wedbush Maintains Outperform on TScan Therapeutics, Raises Price Target to $5
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Wedbush analyst David Nierengarten maintains TScan Therapeutics (NASDAQ:TCRX) with a Outperform and raises the price target from $4 to $5.
Wedbush analyst David Nierengarten maintains TScan Therapeutics (NASDAQ:TCRX) with a Outperform and raises the price target from $4 to $5.